Law Firm Probes Fairness of Four Pending Mergers Including Bio-Techne, Caesars Deals
Image
New York – September 11, 2026 -- Monteverde & Associates PC has opened investigations into four pending mergers, questioning whether shareholders of Bio-Techne, Caesars Entertainment, Colony Bankcorp and Auddia are receiving fair value under the proposed deal terms.
Bio-Techne shareholders face $73.00-per-share cash buyout from Merck KGaA
Bio-Techne Corporation (NASDAQ: TECH) agreed to a sale to Merck KGaA under which shareholders are expected to receive $73.00 per share in cash. Monteverde & Associates is examining whether the price reflects fair value ahead of the deal's closing.